Abstract
With the rapid rise of tumor resistance, combinatorial anticancer therapies have gained favor over singlemolecule inhibition to maximize the suppression of oncogenic pathways. In this regard, HSP90 inhibitors have rapidly emerged as a class of promising drugs that can target multiple oncogenic pathways simultaneously. HSP90 is a highly conserved protein chaperone involved in essential cellular functions such as protein folding and cell signaling in both stressed and unstressed cells. In the last decade, a large number of oncogenic client proteins have been identified to associate with HSP90 and contribute to malignant transformation. Development of HSP90 inhibitors, derived from the natural compound geldanamycin that mimics the ATP binding site of HSP90, was designed to target HSP90 and allow degradation of these client proteins. Preclinical and clinical data with HSP90 inhibitors in various cancer models are promising, and evidences also hint at the potential for tumor-selective cytotoxicity as well as enhanced sensitization to chemo- and radiotherapy. This review will discuss the effects of HSP90 inhibition in cancer, the known mechanistic basis for the oncogenic toxicity and selectivity, as well as the current progress on single or combinatorial therapies with HSP90 inhibitors.
Keywords: HSP90, cancer therapy
Current Medicinal Chemistry
Title: HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy
Volume: 16 Issue: 24
Author(s): Misun Hwang, Luigi Moretti and Bo Lu
Affiliation:
Keywords: HSP90, cancer therapy
Abstract: With the rapid rise of tumor resistance, combinatorial anticancer therapies have gained favor over singlemolecule inhibition to maximize the suppression of oncogenic pathways. In this regard, HSP90 inhibitors have rapidly emerged as a class of promising drugs that can target multiple oncogenic pathways simultaneously. HSP90 is a highly conserved protein chaperone involved in essential cellular functions such as protein folding and cell signaling in both stressed and unstressed cells. In the last decade, a large number of oncogenic client proteins have been identified to associate with HSP90 and contribute to malignant transformation. Development of HSP90 inhibitors, derived from the natural compound geldanamycin that mimics the ATP binding site of HSP90, was designed to target HSP90 and allow degradation of these client proteins. Preclinical and clinical data with HSP90 inhibitors in various cancer models are promising, and evidences also hint at the potential for tumor-selective cytotoxicity as well as enhanced sensitization to chemo- and radiotherapy. This review will discuss the effects of HSP90 inhibition in cancer, the known mechanistic basis for the oncogenic toxicity and selectivity, as well as the current progress on single or combinatorial therapies with HSP90 inhibitors.
Export Options
About this article
Cite this article as:
Hwang Misun, Moretti Luigi and Lu Bo, HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy, Current Medicinal Chemistry 2009; 16 (24) . https://dx.doi.org/10.2174/092986709788802999
DOI https://dx.doi.org/10.2174/092986709788802999 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mesenchymal Stem Cells Promote Caspase Expression in Molt-4 Leukemia Cells <i>Via</i> GSK-3α/Β and ERK1/2 Signaling Pathways as a Therapeutic Strategy
Current Gene Therapy Identification and Characterization of Follistatin-Related Protein-1 Involved in the Regulation of Chinese Perch Skeletal Muscle Hyperplasia
Current Molecular Medicine Nanoparticle Enabled Drug Delivery Across the Blood Brain Barrier: in vivo and in vitro Models, Opportunities and Challenges
Current Pharmaceutical Biotechnology PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention
Current Medicinal Chemistry Cellular Changes, Molecular Pathways and the Immune System Following Photodynamic Treatment
Current Medicinal Chemistry Review of Noscapine and its Analogues as Potential Anti-Cancer Drugs
Mini-Reviews in Organic Chemistry Angiogenic and Vascular Modulation by Extracellular Matrix Cleavage Products
Current Pharmaceutical Design Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
Recent Patents on Anti-Cancer Drug Discovery Metabotropic Purinergic Receptors in Lipid Membrane Microdomains
Current Medicinal Chemistry Potentials and Challenges of Active Targeting at the Tumor Cells by Engineered Polymeric Nanoparticles
Current Pharmaceutical Biotechnology Targeting the BRCA1/2 Tumor Suppressors
Current Drug Targets Monoclonal Antibodies Targeting the Epidermal Growth Factor Receptor
Current Drug Targets Hypericin - A New Antiviral and Antitumor Photosensitizer: Mechanism of Action and Interaction with Biological Macromolecules
Current Drug Targets Artemisia Species as a New Candidate for Diabetes Therapy: A Comprehensive Review
Current Molecular Medicine Nanostructures for Drug Delivery to the Brain
Current Medicinal Chemistry Existing Drug Repurposing for Glioblastoma to Discover Candidate Drugs as a New a Approach
Letters in Drug Design & Discovery Direct Targeting of the Ras GTPase Superfamily Through Structure- Based Design
Current Topics in Medicinal Chemistry Regulation of Cell Migration and Invasion by Specific Modules of uPA: Mechanistic Insights and Specific Inhibitors
Current Drug Targets Recent Advances and Developments in Treatment Strategies Against Pancreatic Cancer
Current Clinical Pharmacology The Biology of the Sodium Iodide Symporter and its Potential for Targeted Gene Delivery
Current Cancer Drug Targets